56 results on '"Erik Stoops"'
Search Results
2. Plasma p‐tau181 concentration accurately predicts clinically diagnosed Alzheimer’s Disease cases
3. Plasma pTau181/Aβ42 identifies cognitive change earlier than CSF pTau181/Ab42
4. A head‐to‐head comparison of plasma phosphorylated tau assays in the real‐world memory clinic
5. Predictive value of a plasma p‐tau181‐specific assay for amyloid accumulation in asymptomatic Alzheimer’s Disease
6. CSF‐plasma biomarker profiles from BioFINDER MCI patients using the same technology
7. Value of plasma biomarkers to predict memory change in cognitively unimpaired individuals
8. First amyloid β1‐42 certified reference material for re‐calibrating commercial immunoassays
9. Plasma P‐tau181 levels predict amyloid pathology in cognitively unimpaired individuals after 10 years
10. Development and analytical characterization of novel tau Simoa assays targeting full‐length tau in CSF and mid‐tau in CSF and plasma
11. Amyloid‐βeta peptides in CSF and plasma discriminate cerebral amyloid angiopathy from controls
12. Development and analytical performance testing of a novel sTREM2 ELISA method to support drug development
13. Plasma biomarkers predict amyloid pathology in cognitively unimpaired individuals
14. Development of an ultrasensitive multiplex assay for simultaneous detection of Aβ1‐42, Aβ1‐40, GFAP and NF‐L in blood
15. Amyloid, pTau, NfL, and GFAP as biomarkers for Alzheimer’s disease
16. Comparison of two analytical platforms for blood‐based surrogate biomarkers of amyloid pathology
17. Cerebrospinal fluid tau biomarkers in the prediction and concordance of neurofibrillary tangle and amyloid pathology
18. Cerebrospinal fluid biomarker levels are not affected by aspiration or gravity drip extraction methods in Alzheimer’s disease: The AIBL study
19. P4‐705: TOWARD RE‐CALIBRATION OF COMMERCIAL IMMUNOASSAYS USING CERTIFIED REFERENCE MATERIALS FOR Aβ 42 IN HUMAN CEREBROSPINAL FLUID
20. F1‐05‐01: LAB‐RELATED PRE‐ANALYTICAL FACTORS INFLUENCING PLASMA AMYLOID BETA CONCENTRATIONS
21. O3‐09‐06: A PROTOTYPE SIMOA ASSAY QUANTIFYING PLASMA AMYLOID BETA 1‐42 AND 1‐40 ISOFORMS CAN DIFFERENTIATE PARTICIPANTS WITH AD FROM HEALTHY CONTROL SUBJECTS
22. O2‐09‐04: HARMONIZATION OF IMMUNOCHEMICAL METHODS FOR MEASUREMENT OF α‐SYNUCLEIN IN HUMAN CEREBROSPINAL FLUID: A ROUND ROBIN STUDY APPROACH
23. P1‐273: EVALUATION OF CERTIFIED REFERENCE MATERIALS FOR BETA‐AMYLOID 1‐42 IN EUROIMMUN BETA‐AMYLOID 1‐42 ELISA AND CHLIA
24. O3‐09‐04: PLASMA AMYLOID β LEVELS, CEREBRAL ATROPHY AND DEMENTIA RISK: THE ROTTERDAM STUDY
25. F2-07-04: PLASMA AMYLOID BETA 1-42 AND 1-40 MEASURED BY A NOVEL SIMOA ASSAY AS A DIAGNOSTIC TOOL FOR ALZHEIMER'S DISEASE PATHOLOGY
26. P1-230: MEMORY FUNCTION IS ASSOCIATED WITH TAU PATHOLOGY IN PARKINSON'S DISEASE
27. [P2–238]: ANALYTICAL PERFORMANCE CHARACTERISTICS OF A PROTOTYPE IMMUNOASSAY FOR QUANTIFICATION OF ALPHA‐SYNUCLEIN IN HUMAN CEREBROSPINAL FLUID
28. [P4–394]: ASSOCIATIONS OF PLASMA AMYLOID BETA LEVELS WITH SEVERITY AND PROGRESSION OF CEREBRAL SMALL VESSEL DISEASE
29. [O1–05–02]: THE CSF Aβ(1–42)/Aβ(1–40) RATIO IMPROVES THE CLINICAL UTILITY OF Aβ(1–42) BY ITS IMPACT AT ANALYTICAL AND CLINICAL LEVELS
30. [P1–237]: DIFFERENTIAL ROLE OF CSF FATTY ACID BINDING PROTEIN 3, α‐SYNUCLEIN AND ALZHEIMER's DISEASE CORE BIOMARKERS IN LEWY BODY DISORDERS AND ALZHEIMER's DEMENTIA
31. [P4–152]: DIFFERENCES IN ANALYTICAL SELECTIVITY OF β‐AMYLOID (1–42) IMMUNOASSAYS EXPLAIN DISCORDANT RESULTS IN STUDY COMPARISONS
32. [P4–151]: ALPHA‐SYNUCLEIN BIOMARKER ANALYSIS: ANALYTICAL PERFORMANCE AND INTER‐LABORATORY PRECISION USING A NEW COLORIMETRIC ELISA
33. [P4–469]: USE FOR CALIBRATION OF CERTIFIED REFERENCE MATERIALS FOR Aβ1–42
34. [P4–468]: PROGRESS ON THE DEVELOPMENT OF CERTIFIED REFERENCE MATERIALS FOR Aβ1–42
35. [P1–271]: A NOVEL COLORIMETRIC ELISA FOR QUANTIFICATION OF TAU, PHOSPHORYLATED AT THREONINE 181, IN CEREBROSPINAL FLUID
36. [P1–280]: ANALYTICAL PERFORMANCE CHARACTERISTICS OF A NOVEL IMMUNOASSAY FOR THE QUANTIFICATION OF BACE‐1 IN HUMAN CEREBROSPINAL FLUID
37. [P3–248]: PLASMA AMYLOID BETA LEVELS, CEREBRAL SMALL‐VESSEL DISEASES AND COGNITION: THE ROTTERDAM STUDY
38. Prevention of tau increase in cerebrospinal fluid of APP transgenic mice suggests downstream effect of BACE1 inhibition
39. P1‐194: Diagnostic Performance of an Automated Elisa System for Alzheimer’s Disease Detection
40. P1‐200: Improvement of Reproducibility for CSF Biomarker Analysis by Integration of Automation in the Test Procedures
41. P4‐316: Standardization of Pre‐Analytical Procedures for Collection and Storage of CSF for the Measurement of Neurogranin Trunc P75 and a‐Synuclein
42. P2‐163: Performance Evaluation of New Absorbance‐Based Elisas for Measuring Different Alpha‐Synuclein (A‐SYN) Species in CSF and Plasma
43. P4‐312: Progress on the Development of Certified Reference Materials for AB1‐42
44. P1‐199: Importance of Different Factors for Analysis of β‐Amyloid Isoforms in CSF and Proposal for an Improved Standard Operating Procedure
45. P3‐188: Performance Testing and Analytical Validation of New Elisas for B‐Amyloid Isoforms (AB(1‐38), AB(1‐40), AB(1‐42)) in Plasma
46. P4‐084: Suppression of TAU Increase in Cerebrospinal Fluid of App Transgenic Mice Provides Evidence for Downstream Effect of Bace1 Inhibition
47. P2‐072: Development of novel elisas for the quantification of both pan‐ApoE and ApoE4 proteins in CSF and blood, and ApoE ε4 phenotyping
48. P4‐039: Fit‐for‐purpose validation of the cerebrospinal fluid markers Aβ1‐40, Aβ1‐42 and total tau
49. O4‐11‐05: The correlation between ß‐amyloid PET‐imaging and cerebrospinal fluid biomarkers is affected by the assay design
50. P3‐089: Measurement of ß‐amyloid isoforms (1‐38, 1‐40, 1‐42) in plasma by new sensitive and accurate elisas
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.